AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37790359 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth delivery of nonpharmacologic care from physical therapists
Number of subjects: 0
Study 37790359 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies focusing on training, education, clinician support, and tailoring physical therapy interventions for telehealth delivery and cultural competency
Number of subjects: 0
Study 37790374 — intervention group
Group type: EXPERIMENTAL
Intervention: Before school closures
Number of subjects: 0
Study 37790374 — intervention group
Group type: COMPARATOR
Intervention: During school closures
Number of subjects: 0
Study 37790451 — intervention group
Group type: EXPERIMENTAL
Intervention: Rule-based segmentation of contrast-enhancing tumor (CE) and intratumoral Fluid using mpMRI
Number of subjects: 285
Study 37790451 — intervention group
Group type: EXPERIMENTAL
Intervention: Rule-based segmentation of High FLAIR (Edema1 + Edema2)
Number of subjects: 285
Study 37790451 — intervention group
Group type: EXPERIMENTAL
Intervention: Model combining time-on-treatment and rule-based volumes of CE and intratumoral Fluid
Number of subjects: 285
Study 37790490 — intervention group
Group type: EXPERIMENTAL
Intervention: ATL-DC + TLR agonist (poly-ICLC)
Number of subjects: 23
Study 37790490 — intervention group
Group type: EXPERIMENTAL
Intervention: ATL-DC + TLR agonist (resiquimod)
Number of subjects: 23
Study 37790490 — intervention group
Group type: EXPERIMENTAL
Intervention: ATL-DC
Number of subjects: 23
Study 37790581 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S vaccine
Number of subjects: 0
Study 37790581 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ vaccine
Number of subjects: 0
Study 37790581 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine
Number of subjects: 0
Study 37790581 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping methods
Number of subjects: 0
Study 37790695 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-motor therapy programme for one month
Number of subjects: 0
Study 37790695 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 37790949 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person training with technical assistance
Number of subjects: 2877
Study 37790949 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person training without technical assistance
Number of subjects: 2877
Study 37790949 — intervention group
Group type: COMPARATOR
Intervention: Website access with technical assistance
Number of subjects: 2877
Study 37791240 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy eating and gardening intervention
Number of subjects: 0
Study 37791242 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Approaches to Stop Hypertension dietary pattern
Number of subjects: 59
Study 37791242 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet tracking application engagement
Number of subjects: 59
Study 37791379 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1-HBV
Number of subjects: 0
Study 37791419 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Antiretroviral Therapy (ART) initiation after diagnosis of AHI
Number of subjects: 20
Study 37791480 — intervention group
Group type: EXPERIMENTAL
Intervention: Target mean arterial blood pressure of 63 mm Hg and liberal oxygen target
Number of subjects: 789
Study 37791480 — intervention group
Group type: COMPARATOR
Intervention: Target mean arterial blood pressure of 77 mm Hg and liberal oxygen target
Number of subjects: 789
Study 37791480 — intervention group
Group type: EXPERIMENTAL
Intervention: Low blood pressure and liberal oxygen target
Number of subjects: 789
Study 37791480 — intervention group
Group type: COMPARATOR
Intervention: High blood pressure and liberal oxygen target
Number of subjects: 789
Study 37791480 — intervention group
Group type: EXPERIMENTAL
Intervention: Low mean arterial blood pressure and liberal oxygen target
Number of subjects: 789
Study 37791610 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher physical quality of life
Number of subjects: 195
Study 37791610 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher mental quality of life
Number of subjects: 195
Study 37791610 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal symptom severity
Number of subjects: 195
Study 37791765 — intervention group
Group type: EXPERIMENTAL
Intervention: pBI-11 DNA vaccine via Tropis biojector
Number of subjects: 0
Study 37791926 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth HIV-prevention educational intervention with dating safety content
Number of subjects: 1087
Study 37791926 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1087
Study 37792065 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (RUX) administered according to the Summary of Product Characteristics
Number of subjects: 928
Study 37792065 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (RUX)
Number of subjects: 928
Study 37792260 — intervention group
Group type: EXPERIMENTAL
Intervention: Inebilizumab
Number of subjects: 160
Study 37792260 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 160
Study 37792369 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin
Number of subjects: 10678
Study 37792369 — intervention group
Group type: COMPARATOR
Intervention: Uncoated aspirin
Number of subjects: 10678
Study 37792378 — intervention group
Group type: EXPERIMENTAL
Intervention: Better Together Physician Coaching (4-month web-based group coaching program)
Number of subjects: 1017
Study 37792378 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1017
Study 37792437 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care facilitation program including medical internet support from human personal pilots and digital interventions (Intervention Group - IG)
Number of subjects: 1020
Study 37792437 — intervention group
Group type: COMPARATOR
Intervention: Only personal support and digital interventions targeting the main symptoms (Active Control Group - ACG)
Number of subjects: 1020
Study 37792437 — intervention group
Group type: COMPARATOR
Intervention: Untreated comparison group (CompG)
Number of subjects: 1020
Study 37792458 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal ultrasound screening
Number of subjects: 25
Study 37792612 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab (200 mg, twice-monthly subcutaneous injection) plus a 14-week prednisone taper
Number of subjects: 118
Study 37792612 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus a 52-week prednisone taper
Number of subjects: 118
Study 37792612 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab
Number of subjects: 118
Study 37792612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 37792613 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray
Number of subjects: 676
Study 37792613 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 676
Study 37792797 — intervention group
Group type: EXPERIMENTAL
Intervention: ORAF intervention (body-centered program)
Number of subjects: 400
Study 37792797 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 400
Study 37793085 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab + Trastuzumab
Number of subjects: 0
Study 37793101 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment, details on dosage and duration not available.
Number of subjects: 0
Study 37793101 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available.
Number of subjects: 0
Study 37793306 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure (ST25, CV12, CV6) for twice-daily therapy at 4 min per intervention for 7 days
Number of subjects: 128
Study 37793306 — intervention group
Group type: COMPARATOR
Intervention: Sham acupressure
Number of subjects: 128
Study 37793679 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion intervention
Number of subjects: 285
Study 37793742 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamic acid (highest vs lowest quartile)
Number of subjects: 3486
Study 37793742 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartic acid (highest vs lowest quartile)
Number of subjects: 3486
Study 37793742 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-aminobutyric acid (highest vs lowest quartile)
Number of subjects: 3486
Study 37793742 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine (highest vs lowest quartile)
Number of subjects: 3486
Study 37793742 — intervention group
Group type: EXPERIMENTAL
Intervention: Log-transformed glutamic acid
Number of subjects: 3486
Study 37793742 — intervention group
Group type: EXPERIMENTAL
Intervention: Log-transformed aspartic acid
Number of subjects: 3486
Study 37793742 — intervention group
Group type: EXPERIMENTAL
Intervention: Log-transformed gamma-aminobutyric acid
Number of subjects: 3486
Study 37793742 — intervention group
Group type: EXPERIMENTAL
Intervention: Log-transformed glycine
Number of subjects: 3486
Study 37793771 — intervention group
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin 2.5 mg/kg intravenously every 21 days
Number of subjects: 325
Study 37793771 — intervention group
Group type: COMPARATOR
Intervention: Pomalidomide 4.0 mg daily (days 1-21) and dexamethasone 40.0 mg weekly in a 28-day cycle
Number of subjects: 325
Study 37793772 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab plus pomalidomide and dexamethasone
Number of subjects: 304
Study 37793772 — intervention group
Group type: COMPARATOR
Intervention: Pomalidomide and dexamethasone
Number of subjects: 304
Study 37793780 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosed prebiotic fibre
Number of subjects: 59
Study 37793792 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab (BKZ) 160 mg subcutaneously every 4 weeks after a 16-week placebo-controlled period
Number of subjects: 0
Study 37793792 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab (BKZ) after switching from placebo at Week 16
Number of subjects: 0
Study 37793792 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab (BKZ)
Number of subjects: 0
Study 37793795 — intervention group
Group type: EXPERIMENTAL
Intervention: CorPath GRX robotic system
Number of subjects: 117
Study 37793853 — intervention group
Group type: EXPERIMENTAL
Intervention: SGN-B7H4V (vedotin ADC)
Number of subjects: 0
Study 37793853 — intervention group
Group type: EXPERIMENTAL
Intervention: SGN-B7H4V (vedotin ADC) as monotherapy
Number of subjects: 0
Study 37793853 — intervention group
Group type: EXPERIMENTAL
Intervention: SGN-B7H4V (vedotin ADC) in combination with anti-PD-1 agent
Number of subjects: 0
Study 37793919 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-prehabilitation group using a tablet, two accelerometers, and a balance board (Khymeia, Padova, Italy)
Number of subjects: 48
Study 37793919 — intervention group
Group type: COMPARATOR
Intervention: Control group using a booklet
Number of subjects: 48
Study 37793919 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-prehabilitation group
Number of subjects: 48
Study 37793919 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 37793933 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (exercise and time-restricted eating)
Number of subjects: 167
Study 37793933 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 167
Study 37793935 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 610
Study 37793935 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption in men
Number of subjects: 610
Study 37793935 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption in individuals of African descent
Number of subjects: 610
Study 37793935 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 610
Study 37794050 — intervention group
Group type: COMPARATOR
Intervention: HER2-positive patients
Number of subjects: 3582
Study 37794050 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2-low patients
Number of subjects: 3582
Study 37794054 — intervention group
Group type: EXPERIMENTAL
Intervention: AI diagnosis (intervention group)
Number of subjects: 993
Study 37794054 — intervention group
Group type: COMPARATOR
Intervention: No AI diagnosis (control group)
Number of subjects: 993
Study 37794139 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac bone graft mixed with bone marrow aspirate concentrate
Number of subjects: 36
Study 37794139 — intervention group
Group type: COMPARATOR
Intervention: Iliac bone graft alone
Number of subjects: 36
Study 37794185 — intervention group
Group type: EXPERIMENTAL
Intervention: PTPN2/PTPN1 inhibitor ABBV-CLS-484
Number of subjects: 0
Study 37794185 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37794220 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatments from five phase II/III studies (Gem/Cis, Ro96, RC57, ACCEPT, RASH)
Number of subjects: 912
Study 37794220 — intervention group
Group type: EXPERIMENTAL
Intervention: RC57 treatment
Number of subjects: 912
Study 37794220 — intervention group
Group type: EXPERIMENTAL
Intervention: RASH treatment
Number of subjects: 912
Study 37794220 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous treatment lines > 1
Number of subjects: 912
Study 37794220 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance status
Number of subjects: 912
Study 37794246 — intervention group
Group type: EXPERIMENTAL
Intervention: NNS beverages
Number of subjects: 493
Study 37794246 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 493
Study 37794275 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatology Life Quality Index (DLQI)
Number of subjects: 111
Study 37794275 — intervention group
Group type: EXPERIMENTAL
Intervention: Epworth Sleepiness Scale (ESS)
Number of subjects: 111
Study 37794275 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalpdex
Number of subjects: 111
Study 37794275 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Lichen Planus Symptom Severity Measure (OLPSSM)
Number of subjects: 111
Study 37794281 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (4000 IU qd)
Number of subjects: 0
Study 37794281 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (70 IU Kg)
Number of subjects: 0
Study 37794281 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37794334 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent supplemental oxygen (SO)
Number of subjects: 202
Study 37794334 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous supplemental oxygen (SO)
Number of subjects: 202
Study 37794334 — intervention group
Group type: COMPARATOR
Intervention: Room air (RA)
Number of subjects: 202
Study 37794395 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-calorie ketogenic diet (VLCKD)
Number of subjects: 0
Study 37794395 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric balanced diet (HBD)
Number of subjects: 0
Study 37794431 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine (intradermal administration)
Number of subjects: 1800
Study 37794431 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 1800
Study 37794432 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL-IB
Number of subjects: 85
Study 37794432 — intervention group
Group type: COMPARATOR
Intervention: ACL-R
Number of subjects: 85
Study 37794453 — intervention group
Group type: EXPERIMENTAL
Intervention: ESUS recurrence score value ≥ 7
Number of subjects: 238
Study 37794453 — intervention group
Group type: COMPARATOR
Intervention: Low-risk group (score 0-4)
Number of subjects: 238
Study 37794453 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-risk group (score 5-6)
Number of subjects: 238
Study 37794453 — intervention group
Group type: COMPARATOR
Intervention: High-risk group (score ≥ 7)
Number of subjects: 238
Study 37794453 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 238
Study 37794472 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS tapering regimen (initial ICS dose reduced by 50% for 8 weeks followed by total ICS removal)
Number of subjects: 110
Study 37794472 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (no specific details provided)
Number of subjects: 110
Study 37794472 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS tapering regimen
Number of subjects: 110
Study 37794480 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Breast Tomosynthesis (DBT)
Number of subjects: 14730
Study 37794480 — intervention group
Group type: COMPARATOR
Intervention: Digital Mammography (DM)
Number of subjects: 14730
Study 37794523 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone text messaging plus motivational interviewing
Number of subjects: 275
Study 37794523 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 275
Study 37794564 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing with a 385 gene kidney disease panel (Renasight TM test)
Number of subjects: 1623
Study 37794590 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified cell manufacturing process in first-in-human clinical trial of Cas9-engineered T cells (NCT03399448)
Number of subjects: 0
Study 37794590 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of p53
Number of subjects: 0
Study 37794604 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic-based intervention
Number of subjects: 484
Study 37794604 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 484
Study 37794659 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal corticosteroids (INCS) - 220 μg triamcinolone acetonide twice daily for 14 days prior to nasal allergen challenge (NAC)
Number of subjects: 20
Study 37794659 — intervention group
Group type: COMPARATOR
Intervention: Control saline challenge
Number of subjects: 20
Study 37794659 — intervention group
Group type: COMPARATOR
Intervention: NAC with no treatment intervention
Number of subjects: 20
Study 37794659 — intervention group
Group type: COMPARATOR
Intervention: NAC with 14 days pre-treatment with saline nasal spray (placebo)
Number of subjects: 20
Study 37794725 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimulation of sleep slow waves
Number of subjects: 0
Study 37794725 — intervention group
Group type: COMPARATOR
Intervention: Control group (no auditory stimulation)
Number of subjects: 0
Study 37794745 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide oral solution, administered twice daily (BID) for 6 months
Number of subjects: 422
Study 37794745 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered twice daily (BID) for 6 months
Number of subjects: 422
Study 37794745 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide oral solution
Number of subjects: 422
Study 37794745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study 37794802 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model using clinical, laboratory, and demographic data to predict class of variability.
Number of subjects: 5030
Study 37794802 — intervention group
Group type: EXPERIMENTAL
Intervention: Measure of variability in ALSFRS-R scores.
Number of subjects: 5030
Study 37794802 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced set of 16 predictors from the machine learning model.
Number of subjects: 5030
Study 37794802 — intervention group
Group type: EXPERIMENTAL
Intervention: Variability in disease progression in fast-progressing patients.
Number of subjects: 5030
Study 37794803 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin with chemotherapy
Number of subjects: 0
Study 37794814 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-epithelial connective tissue graft
Number of subjects: 102
Study 37794830 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical treatment for bile acid diarrhoea
Number of subjects: 251
Study 37794830 — intervention group
Group type: EXPERIMENTAL
Intervention: C4 > 46 ng/mL
Number of subjects: 251
Study 37794830 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision tree combining C4 ≥ 31 ng/mL with ≥1.1 daily watery stools (Bristol type 6 and 7)
Number of subjects: 251
Study 37794830 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model including C4, sum of measured stool bile acids, and daily watery stools
Number of subjects: 251
Study 37794845 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA treatment
Number of subjects: 430
Study 37794870 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized e-coaching based on baseline activity patterns
Number of subjects: 2458
Study 37794870 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily prompts to complete 10,000 steps
Number of subjects: 2458
Study 37794870 — intervention group
Group type: EXPERIMENTAL
Intervention: Hourly prompts to stand following inactivity
Number of subjects: 2458
Study 37794870 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily instructions to read AHA guidelines
Number of subjects: 2458
Study 37794868 — intervention group
Group type: EXPERIMENTAL
Intervention: PPG-based wearable
Number of subjects: 92
Study 37794868 — intervention group
Group type: COMPARATOR
Intervention: Holter ECG (control)
Number of subjects: 92
Study 37794880 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy with the Penumbra System (ADAPT)
Number of subjects: 167
Study 37794880 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy with the Penumbra System (ADAPT + 3D)
Number of subjects: 167
Study 37794880 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy with the Penumbra System
Number of subjects: 167
Study 37794909 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided mindfulness meditation
Number of subjects: 0
Study 37794909 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided yoga
Number of subjects: 0
Study 37794909 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided brisk walking
Number of subjects: 0
Study 37794909 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (self-directed stress management)
Number of subjects: 0
Study 37795393 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-of-care SBRT (24 Gy in 2 fractions)
Number of subjects: 0